New shot takes aim at Hard-to-Treat blood cancers
NCT ID NCT07574346
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This early study tests an experimental injection called IASO207 in 18 adults with B-cell blood cancers (like lymphoma) that returned or didn't respond to standard treatment. The main goals are to check safety and find the right dose, while also seeing if it shrinks tumors. Participants must be between 18 and 75 years old and have certain types of lymphoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.